Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide for Early COVID-19 Treatment
NCT05087381Phase 4Completed
- Sponsor
- Chulalongkorn University
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fluvoxamine, bromhexine, cyproheptadine, niclosamide in coronavirus disease 2019 (COVID-19), sponsored by Chulalongkorn University. Started Oct 2021; status: completed.
02
Drugs
fluvoxaminebromhexinecyproheptadineniclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05087381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087381.